Once the peptide reaches the bloodstream the mechanism is identical. The difference is how much gets there. Sermorelin is a fragment of growth hormone releasing hormone, and peptides of that size cross the lining of the mouth badly. No published study establishes that a sublingual preparation delivers a dose comparable to a subcutaneous injection.
The mechanism both routes are aiming at
Growth hormone releasing hormone is a hypothalamic peptide that acts on receptors in the anterior pituitary to trigger release of stored growth hormone. Sermorelin corresponds to the first twenty nine amino acids of that molecule, the shortest segment retaining biological activity. The pharmacology has been described since the mid nineteen eighties.
The clinically interesting feature is that this acts one step upstream of growth hormone itself. Rather than supplying the hormone, it prompts the pituitary to release its own in a pattern that follows the body’s pulsatile rhythm. Research on pulsatile secretagogue control of growth hormone release in healthy men shows how sensitive that rhythm is to what is given and when. Feedback loops remain intact, which is the argument usually made for this class over direct growth hormone administration.
All of that depends on the peptide arriving in circulation intact and in sufficient quantity. Nothing about the receptor changes with route. Everything about delivery does.
Why the delivery problem is the real difference
Peptides are fragile molecules for oral and mucosal delivery. They are broken down by enzymes, they are large and water loving compared with the small lipophilic molecules that cross membranes easily, and the tissues of the mouth present a physical barrier. Reviews of oral peptide delivery describe this consistently, and a body of formulation research exists specifically to work around it, using permeation enhancers, nanoparticle carriers, and oromucosal film systems. That research would not exist if the barrier were easy to cross.
For this particular peptide there is one relevant human measurement. A study in thirty healthy men administered the twenty nine amino acid analog either intravenously or through the nasal mucosa. Absorption across the nasal surface was low, with bioavailability reported in the low single digit percentage range, and a considerably larger quantity had to be delivered by that route to produce a growth hormone response similar to the intravenous one.
Nasal mucosa is not sublingual mucosa, and that work dates from nineteen ninety three. It should be read as the closest available evidence rather than as a direct answer. What it does establish is that mucosal delivery of this molecule was measured, found to be inefficient, and required compensation. Sublingual preparations sold today have not been characterized this way in published literature at all.
What the human evidence actually covers
| Route | What has been studied in humans |
|---|---|
| Subcutaneous injection | Controlled trials of growth hormone releasing hormone analogs measuring growth hormone and insulin-like growth factor response, cognition, immune markers, and visceral fat |
| Intravenous | Pharmacokinetic and pituitary stimulation studies establishing the dose response relationship |
| Intranasal | One pharmacokinetic study in healthy men reporting low mucosal absorption |
| Sublingual | No published bioequivalence or pharmacokinetic comparison against injection |
The injection column is where the real trial base sits. A randomized study of the long acting analog CJC-1295 in healthy adults tracked sustained increases in growth hormone and insulin-like growth factor after subcutaneous administration. A twenty week controlled trial of subcutaneous tesamorelin examined cognitive outcomes in older adults. A randomized trial of tesamorelin in people with HIV and abdominal fat accumulation measured visceral and liver fat by imaging. Every one of those used an injection.
What expected results can honestly mean
For an approved injectable analog in a defined population, expected results have a meaning grounded in trial data. For a compounded preparation of sermorelin in a healthy adult, they do not. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality, so there is no product level evidence to point at. The literature specifically supporting sermorelin in adults is thinner than most marketing implies, with the most frequently cited adult item being a short commentary rather than a trial.
That makes the source of the prescription unusually important. Endocrinology practices, longevity clinics, and supervised online prescribers each frame this differently, and it is fair to ask the provider behind it what evidence they are relying on for the specific preparation and route being offered, and what they expect to measure. A program that answers with hormone panels and a defined review point is describing something testable. One that answers with vitality is not.
What is not established
Anti-aging benefit in healthy adults is not established. Neither is muscle growth, fat loss, or athletic performance. Reviews of growth hormone in sport have consistently found the performance evidence weak, and an umbrella review of performance enhancing substances in healthy athletes reached the same conclusion. There is no approved product for any of those uses, and no compounded preparation carries approval for them either.
What can be said is narrower and more useful. Growth hormone releasing hormone analogs raise growth hormone and insulin-like growth factor levels when enough of the peptide reaches the pituitary. Whether a sublingual preparation achieves that is an open question, and the honest position is that it has not been demonstrated.
The same telehealth companies that sell peptides often list categories with far sturdier evidence, which is a useful contrast for a buyer to hold in mind. Erectile dysfunction is the clearest example: the oral drugs behind most ED treatment programs, whether offered through Hims and Hers, Ro, or HealthRX, carry decades of randomized trials and approved labeling. Sermorelin’s anti-aging use has none of that, so a provider’s fluency in one category says nothing about the evidence behind another.
Frequently asked questions
Does sublingual bypass the digestive system?
Partly, which is the rationale for the route. Avoiding the stomach does not solve the harder problem, since the tissues of the mouth are themselves a substantial barrier to peptides and enzymes are present there too. Bypassing one obstacle is not the same as achieving absorption.
Is there any bioequivalence data for sublingual sermorelin?
No published bioequivalence study compares a sublingual preparation with a subcutaneous injection of this peptide. Route claims for compounded peptides rest on pharmacological reasoning and inference. Anyone presenting the two as interchangeable is stating something the literature does not support.
Why do injectable analogs have more evidence?
Because they were developed as pharmaceutical products and studied that way. Tesamorelin, a stabilized analog, went through randomized trials and holds an approval in a defined population. Compounded preparations do not go through that process, so the evidence base does not follow them.
Does raising growth hormone levels guarantee a benefit?
No. A measurable rise in growth hormone or insulin-like growth factor is a biochemical change, not a clinical outcome. Trials in healthy older adults have measured such rises alongside modest or mixed effects on the outcomes people actually care about.
Is sermorelin the same as growth hormone?
No. Growth hormone is the hormone itself, supplied as an approved injectable product for defined indications. Sermorelin acts upstream on the pituitary to prompt release of the body’s own supply, which is a different mechanism with a different evidence base.
Sources
- Growth hormone releasing hormone. PubMed: https://pubmed.ncbi.nlm.nih.gov/2429796/
- Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 after intravenous or intranasal administration. PubMed: https://pubmed.ncbi.nlm.nih.gov/8329825/
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. PubMed: https://pubmed.ncbi.nlm.nih.gov/16352683/
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. PubMed: https://pubmed.ncbi.nlm.nih.gov/25038357/
- Differential pulsatile secretagogue control of GH secretion in healthy men. PubMed: https://pubmed.ncbi.nlm.nih.gov/23485864/
- Overcoming Oral Cavity Barriers for Peptide Delivery Using Advanced Pharmaceutical Techniques and Nano-Formulation Platforms. PubMed: https://pubmed.ncbi.nlm.nih.gov/41301828/
- Oral peptide delivery: Translational challenges due to physiological effects. PubMed: https://pubmed.ncbi.nlm.nih.gov/30145135/
- Growth hormone doping in sports: a critical review of use and detection strategies. PubMed: https://pubmed.ncbi.nlm.nih.gov/22368183/
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? PubMed: https://pubmed.ncbi.nlm.nih.gov/18046908/
- FDA, Compounding and the FDA: Questions and Answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
